Eli Lilly candidate shows weight loss at 11 percent in phase III trial

Initial test results form Eli Lilly's phase III study show that the drug candidate tirzepatide can generate an 11 percent weight loss with the highest tested dosis at 15 mg.

Photo: Mike Blake/REUTERS / X00030

US pharmaceutical firm Eli Lilly have oresented the initial results for the phase III study for the company's drug candidate tirzepatide against obesity.

The preliminary results from the Surpass trial program shows a placebo-adjusted weight reduction at 8.8 kg with a 15 mg dosis, which is the highest tested dosis and a 6.3 kg weight reduction with the lowest dosis at 5 mg, as stated by the firm in a press announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs